CA2520391C - Nouveaux derives de cyclodextrines, leur procede de preparation et leur utilisation notamment pour la solubilisation de substances pharmacologiquement actives - Google Patents

Nouveaux derives de cyclodextrines, leur procede de preparation et leur utilisation notamment pour la solubilisation de substances pharmacologiquement actives Download PDF

Info

Publication number
CA2520391C
CA2520391C CA2520391A CA2520391A CA2520391C CA 2520391 C CA2520391 C CA 2520391C CA 2520391 A CA2520391 A CA 2520391A CA 2520391 A CA2520391 A CA 2520391A CA 2520391 C CA2520391 C CA 2520391C
Authority
CA
Canada
Prior art keywords
formula
compound
group
viii
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2520391A
Other languages
English (en)
French (fr)
Other versions
CA2520391A1 (fr
Inventor
Jacques Defaye
Carmen Ortiz-Mellet
Jose Manuel Garcia-Fernandez
Maria Gomez-Garcia
Kazimierz Chmurski
Jian-Xin Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Científicas
Universidad de Sevilla
Centre National de la Recherche Scientifique
Joseph Fourier University
Original Assignee
Consejo Superior de Investigaciones Científicas
Universidad de Sevilla
Centre National de la Recherche Scientifique
Joseph Fourier University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Centre National de la Recherche Scientifique, Joseph Fourier University filed Critical Consejo Superior de Investigaciones Científicas
Publication of CA2520391A1 publication Critical patent/CA2520391A1/fr
Application granted granted Critical
Publication of CA2520391C publication Critical patent/CA2520391C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA2520391A 2003-03-28 2004-03-22 Nouveaux derives de cyclodextrines, leur procede de preparation et leur utilisation notamment pour la solubilisation de substances pharmacologiquement actives Expired - Fee Related CA2520391C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0303899A FR2852959B1 (fr) 2003-03-28 2003-03-28 Nouveaux derives de cyclodextrines, leur procede de preparation et leur utilisation notamment pour solubilisation de substances pharmacologiquement actives
FR03/03899 2003-03-28
PCT/FR2004/000691 WO2004087768A1 (fr) 2003-03-28 2004-03-22 Nouveaux derives de cyclodextrines, leur procede de preparation et leur utilisation notamment pour la solubilisation de substances pharmacologiquement actives

Publications (2)

Publication Number Publication Date
CA2520391A1 CA2520391A1 (fr) 2004-10-14
CA2520391C true CA2520391C (fr) 2012-11-20

Family

ID=32947275

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2520391A Expired - Fee Related CA2520391C (fr) 2003-03-28 2004-03-22 Nouveaux derives de cyclodextrines, leur procede de preparation et leur utilisation notamment pour la solubilisation de substances pharmacologiquement actives

Country Status (9)

Country Link
US (2) US7632941B2 (enExample)
EP (1) EP1608687B1 (enExample)
JP (1) JP5054970B2 (enExample)
AT (1) ATE455795T1 (enExample)
CA (1) CA2520391C (enExample)
DE (1) DE602004025213D1 (enExample)
ES (1) ES2338558T3 (enExample)
FR (1) FR2852959B1 (enExample)
WO (1) WO2004087768A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080234182A1 (en) * 2007-03-22 2008-09-25 Innovative Biologics, Inc. Blockers of pore-forming virulence factors and their use as anti-infectives
EP1735326A4 (en) * 2004-01-29 2011-04-20 Pinnacle Pharmaceuticals BETA-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST LETHAL ANTHRAX TOXIN
AU2005240122B2 (en) 2004-05-03 2011-02-17 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
CN101151037A (zh) 2005-01-28 2008-03-26 平纳克尔医药股份有限公司 作为抗菌剂的β-环糊精衍生物
ES2294926B1 (es) * 2006-05-11 2009-02-16 Universidad De Sevilla Nuevos derivados de ciclodextrinas selectivamente funcionalizados en su cara secundaria, procedimiento de preparacion y utilizacion de los mismos.
FR2903987B1 (fr) * 2006-07-21 2012-12-21 Centre Nat Rech Scient Nouveaux derives de cyclodextrines amphiphiles, leur utilisation dans les domaines pharmaceutiques,cosmetiques, alimentaires et leur application a la production de nouveaux nanosystemes
US8592611B2 (en) * 2008-07-17 2013-11-26 The Johns Hopkins University Trioxane dimer sulfur compounds
WO2010017328A2 (en) * 2008-08-06 2010-02-11 Rgo Biosciences Llc Cyclodextrin conjugates
WO2015179963A1 (en) 2014-05-29 2015-12-03 Uti Limited Partnership Cyclodextrin-based polyanionic and non-ionic dendrimers
CN109762042B (zh) * 2018-09-21 2022-04-08 河北艾克美冀生物科技有限公司 一种治疗癌症的药物、其合成方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2648464B1 (fr) * 1989-06-14 1991-08-30 Commissariat Energie Atomique Derives de cyclomalto-oligosaccharides et leurs procedes de preparation
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法と用途
US5684169A (en) * 1992-11-27 1997-11-04 Ensuiko Sugar Refining Co., Ltd. Cyclodextrin inclusion complex of taxol, and method for its production and its use
US5959089A (en) * 1993-07-19 1999-09-28 Hannessian; Stephen Amino-cyclodextrin syntheses
FR2715307B1 (fr) * 1994-01-25 1996-04-05 Commissariat Energie Atomique Procédé de solubilisation dans un milieu aqueux d'agents antitumoraux de la famille du taxol, et cyclodextrines ramifiées utilisables pour cette solubilisation.
FR2716200B1 (fr) * 1994-02-11 1996-04-26 Commissariat Energie Atomique Procédé de préparation de cyclomaltooligosaccharides ramifiés, en particulier de cyclodextrines ramifiées.
FR2746103B1 (fr) * 1996-03-14 1998-07-24 Thioureido-cyclodextrines, utilisables en particulier pour solubiliser des agents antitumoraux et antiparasitaires et leurs procedes de preparation
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US6157642A (en) 1997-10-14 2000-12-05 Teledesic Llc Coding system and method for low-earth orbit satellite data communication
FI980489A7 (fi) * 1998-03-04 1999-09-05 Alexei Radievich Khomutov Syklodekstriinien uudet johdannaiset

Also Published As

Publication number Publication date
DE602004025213D1 (de) 2010-03-11
JP5054970B2 (ja) 2012-10-24
ATE455795T1 (de) 2010-02-15
US7632941B2 (en) 2009-12-15
US8440814B2 (en) 2013-05-14
US20090264540A1 (en) 2009-10-22
FR2852959A1 (fr) 2004-10-01
FR2852959B1 (fr) 2008-02-15
WO2004087768A1 (fr) 2004-10-14
JP2006521440A (ja) 2006-09-21
CA2520391A1 (fr) 2004-10-14
EP1608687A1 (fr) 2005-12-28
US20070167401A1 (en) 2007-07-19
ES2338558T3 (es) 2010-05-10
EP1608687B1 (fr) 2010-01-20

Similar Documents

Publication Publication Date Title
JP4087900B2 (ja) 新規シクロデキストリン−誘導体およびその製造法
US8440814B2 (en) Derivatives of cyclodextrins, process for their preparation and their use in particular for solubilizing pharmacologically active substances
US20100093662A1 (en) Novel amphiphilic cyclodextrin derivatives
FR2814463A1 (fr) Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
FR2935386A1 (fr) Nouveaux polysaccharides a activite antithrombotique comprenant une liaion covalente avec une chaine amine
US5821349A (en) Derivatives of cyclodextrins, their preparation and their use for incorporating hydrophobic molecules into organized surfactant systems
EP1689789B1 (fr) Dimeres de cyclodextrines et leurs derives, leurs procedes de preparation et leur utilisation notamment pour la solubilisation de substances pharmacologiquement actives
JP3865436B2 (ja) 分岐シクロデキストリンの製造方法
EP0886654B1 (fr) Thioureido-cyclodextrines, utilisables en particulier pour solubiliser des agents antitumoraux et antiparasitaires et leurs procedes de preparation
CA2577258C (fr) Hexadecasaccharides biotinyles, leur preparation et leur utilisation comme anticoagulants et antithrombotique de l'heparine
JP5144957B2 (ja) 多分岐シクロデキストリン化合物、その製造方法、および標的指向性薬物送達システム用の薬物送達剤
JP3816554B2 (ja) 新規分岐シクロデキストリンおよびその製造方法
Gupta et al. Glycodendrimers: endlessly evolving architecture design, synthetic strategies, and biological applications
FR2964660A1 (fr) Nouveaux polysaccharides biotinyles a activite antithrombotique et presentant une stabilite metabolique amelioree
WO2012042123A1 (fr) Polysaccharides biotinyles a activite antithrombotique et presentant une stabilite metabolique amelioree

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150323